Compare LESL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | HCWB |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 14.8M |
| IPO Year | 2020 | 2021 |
| Metric | LESL | HCWB |
|---|---|---|
| Price | $9.70 | $1.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $2.54 | ★ $35.00 |
| AVG Volume (30 Days) | 496.3K | ★ 1.1M |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $1,241,915,000.00 | $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | $3.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.25 |
| 52 Week High | $10.48 | $7.35 |
| Indicator | LESL | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 71.48 | 43.36 |
| Support Level | $0.99 | $1.03 |
| Resistance Level | N/A | $1.17 |
| Average True Range (ATR) | 1.54 | 0.16 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 86.54 | 23.53 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.